WAVE LIFE SCIENCES LTD. Property, Plant and Equipment, Gross
WAVE LIFE SCIENCES LTD. (WVE) had Property, Plant and Equipment, Gross of $56.93 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:PropertyPlantAndEquipmentGross · last filed 2026-02-26
- 2025-12-31: Property, Plant and Equipment, Gross $56.93M.
- 2024-12-31: Property, Plant and Equipment, Gross $56.46M.
- 2023-12-31: Property, Plant and Equipment, Gross $55.79M.
- 2022-12-31: Property, Plant and Equipment, Gross $55.13M.
| Period end | Property, Plant and Equipment, Gross |
|---|---|
| 2025-12-31 | $56.93M 10-K · filed 2026-02-26 |
| 2024-12-31 | $56.46M 10-K · filed 2026-02-26 |
| 2023-12-31 | $55.79M 10-K · filed 2025-03-04 |
| 2022-12-31 | $55.13M 10-K · filed 2024-03-06 |
| 2021-12-31 | $54.50M 10-K · filed 2023-03-23 |
| 2020-12-31 | $54.09M 10-K · filed 2022-03-03 |
| 2019-12-31 | $53.37M 10-K · filed 2021-03-04 |
| 2018-12-31 | $49.43M 10-K · filed 2020-03-02 |
| 2017-12-31 | $31.75M 10-K · filed 2019-03-01 |
| 2016-12-31 | $11.10M 10-K · filed 2018-03-12 |
| 2015-12-31 | $4.40M 10-K · filed 2017-03-16 |
| 2015-09-30 | $3.72M 10-Q · filed 2015-12-17 |
| 2014-12-31 | $2.48M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |